Zimmer Biomet's Ivan Tornos Joins OREF Board to Boost Musculoskeletal Research Efforts
- Ivan Tornos, CEO of Zimmer Biomet, joins the OREF Board to enhance collaboration in musculoskeletal research.
- His leadership aims to increase funding for MSK research, addressing significant patient care challenges and economic impacts.
- Tornos and OREF plan to leverage resources to improve MSK health outcomes and advocate for research investment.
Zimmer Biomet's Ivan Tornos Joins OREF Board to Advance MSK Research
Ivan Tornos, the newly appointed Chairman, President, and CEO of Zimmer Biomet Holdings, has been welcomed onto the Board of Trustees for the Orthopaedic Research and Education Foundation (OREF). Since his arrival at Zimmer Biomet in 2018 and subsequent promotion to CEO in 2023, Tornos has played a crucial role in steering the company, a major player in the musculoskeletal (MSK) health industry. His appointment to the OREF board signals a strengthened partnership between the two organizations, both of which share a dedication to improving patient care and addressing the pressing challenges facing those with musculoskeletal conditions.
OREF Board President Joshua J. Jacobs, MD, expresses enthusiasm for Tornos’ leadership and vision. He underscores the importance of collaboration between OREF and Zimmer Biomet, particularly in the context of MSK research funding, which remains alarmingly low despite the significant economic impact of these conditions. With over half of the adult population in the U.S. affected by MSK issues, costing nearly $980 billion annually, the urgency to advance research and improve treatment options is more critical than ever. Tornos’ leadership within the OREF is expected to enhance advocacy efforts aimed at increasing funding for MSK research, which is vital for improving patient outcomes and reducing the economic burden on healthcare systems.
Tornos expresses a commitment to accelerating research efforts, emphasizing that many patients currently do not receive the effective solutions they need. The OREF is recognized for its advocacy in prioritizing funding for MSK research, with evidence that grantees have a higher success rate in securing additional funding from the National Institutes of Health (NIH). Notably, the success rate for OREF grant recipients stands at 23.5%, outperforming the overall NIH funding success rate. This collaboration may serve to not only bolster OREF's mission but also to amplify the visibility of MSK research, ultimately benefiting patients and healthcare providers alike.
In other developments, the OREF continues to champion the need for increased investment in MSK research as a cornerstone of national healthcare improvements. As Tornos integrates into his role on the board, both he and OREF anticipate leveraging their combined resources to address the funding disparities that hinder progress in this critical area of health. The foundation’s proactive approach, alongside Tornos’ industry insights, is poised to facilitate meaningful advancements in musculoskeletal health in the coming years.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

